Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Interstitial Lung Disease: early-phase trial registry
27 of 37 indexed Interstitial Lung Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #406 of 28,707 conditions by registered trial count.
37 US clinical trials · 27 currently recruiting · #406 of 28,707 conditions by registered trial count
Interstitial Lung Disease: 37 US clinical trials tracked, 27 recruiting.
Interstitial Lung Disease is the subject of 37 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Bastiaan Driehuys, running 3 of these trials.
Enrollment posture brief
Registry condition interstitial-lung-disease
OPEN 27 | RECR 73% | LATE 3 | EARLY 17 | RANK #406 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adult (73% recruiting · 11 trials)
Interstitial Lung Disease lists 27 open slots (73% of 37 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Interstitial Lung Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Interstitial Lung Disease is recruiting above its size-band peers.
27 of 37 indexed trials (73%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Interstitial Lung Disease trials is spread across many organizations.
Bastiaan Driehuys accounts for 3 of 37 trials (8.1%). 28 distinct sponsors appear on at least one study for this condition label.
-
Typical Interstitial Lung Disease enrolment sits around 125 participants.
Median target enrolment is 125 among the 37 trials that report a genuine target (sentinel values excluded). 16 of those (43.2%) plan for fewer than 100 participants.
-
Interstitial Lung Disease splits between interventional and observational designs.
24 interventional and 13 observational studies make up this index (64.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
37 total, page 1 of 1
Pulmonary Fibrosis Foundation Community Registry
Pulmonary Fibrosis Foundation
NCT05382572
WTC Chest CT Imaging Archive
Icahn School of Medicine at Mount Sinai
NCT03295279
Interstitial Lung Disease Research Unit Biobank
University of Kansas Medical Center
NCT05392881
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
United Therapeutics
NCT06388421
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
University of Colorado, Denver
NCT03297775
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics
NCT05943535
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
Mayo Clinic
NCT03478826
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
University of Massachusetts, Worcester
NCT06855329
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
University of Colorado, Denver
NCT06397677
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
Bastiaan Driehuys
NCT01280994
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Insmed Incorporated
NCT07179380
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
United Therapeutics
NCT05776225
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Mario Castro, MD, MPH
NCT04624490
SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
Medical University of South Carolina
NCT07269262
129Xe MRI Cardiopulmonary
Bastiaan Driehuys
NCT06038630
Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research
Baylor Research Institute
NCT04664192
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
Children's Hospital Medical Center, Cincinnati
NCT04925375
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
National Institute of Environmental Health Sciences (NIEHS)
NCT06325696
Pulmonary Hypertension SOLAR
Bastiaan Driehuys
NCT04778046
FAPI PET for Lung Fibrosis
University of California, Los Angeles
NCT05365802
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
MGH Institute of Health Professions
NCT06304207
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
Massachusetts General Hospital
NCT05417776
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
Memorial Sloan Kettering Cancer Center
NCT07323732
Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough
Mayo Clinic
NCT05120934
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Pharma
NCT05892614
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Paul Szabolcs
NCT03630211
Feasibility of Semaglutide in Advanced Lung Disease
University of Pennsylvania
NCT05746039
Genentech Validation Tool for Pulmonary Fibrosis
Columbia University
NCT04676594
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT05270668
A Study of Mosliciguat in PH-ILD
Pulmovant
NCT06635850
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Liquidia Technologies
NCT06129240
Autologous Stem Cell Treatment for Chronic Lung Disease Study
Lung Institute
NCT03044431
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
Icahn School of Medicine at Mount Sinai
NCT04619680
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Michael Roth
NCT03221257
Palliative Care Planner (PCplanner)
Duke University
NCT05095363
Comparison of Transbronchial, Cryoprobe and VATS Biopsy For the Diagnosis of Interstitial Lung Disease (ILD)
Duke University
NCT01972685
Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)
Mayo Clinic
NCT03929120
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 13 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Interstitial Lung Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Interstitial Lung Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Interstitial Lung Disease page
37 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Interstitial Lung Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bastiaan Driehuys sponsors the most Interstitial Lung Disease trials on record, review their full trial history before evaluating a specific study. See Bastiaan Driehuys's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Interstitial Lung Disease condition card totals 37 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.